title: [A clinical evaluation of fluconazole in deep seated fungal infections associated with hematological disorders].
abstract: The effectiveness of fluconazole on deep seated fungal infections associated with hematological disorders was evaluated in a multicenter clinical study. The underlying diseases included acute myeloblastic leukemia, acute lymphocytic leukemia, malignant lymphoma, adult T cell leukemia, multiple myeloma and others. Fluconazole (FLCZ) was administrated 100-400 mg/day intravenously or orally to 79 patients with systemic fungal infections complicated with hematological disorders and it was possible to evaluate clinical efficacies in 60 patients. 27 patients were diagnosed as having determinate systemic fungal infections and 33 patients suspected fungal infections. The clinical efficacies were 81.5% (22/27) in patients with diagnosed fungal infections and 57.6% (19/33) in patients with suspected fungal infections. The overall clinical efficacy was 68.3% (41/60). No side effects such as gastrointestinal symptoms, vascular pain and renal dysfunction were observed in this study. As for abnormal laboratory test, transient increases in GOT, GPT, Al-P, LDH, serum Na, Cl and decrease in serum K were observed in 9 patients (11.4%). These results indicated that FLCZ has a high therapeutic efficacy on deep seated fungal infections in patients with hematological disorders.
authors.affiliation: First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Murakami
authors.forename: M
authors.initials: M
authors.lastname: Misago
authors.forename: S
authors.initials: S
authors.lastname: Tohnai
authors.forename: M
authors.initials: M
authors.lastname: Nakanishi
authors.forename: R
authors.initials: R
authors.lastname: Ogawa
authors.forename: A
authors.initials: A
authors.lastname: Wake
authors.forename: K
authors.initials: K
authors.lastname: Nagata
authors.forename: N
authors.initials: N
authors.lastname: Mori
authors.forename: J
authors.initials: J
authors.lastname: Tsukada
authors.forename: K
authors.initials: K
authors.lastname: Nakata
authors.forename: S
authors.initials: S
authors.lastname: Oda
authors.forename: I
authors.initials: I
authors.lastname: Morimoto
authors.forename: S
authors.initials: S
authors.lastname: Eto
authors.forename: Y
authors.initials: Y
authors.lastname: Izumi
authors.forename: H
authors.initials: H
authors.lastname: Sawada
authors.forename: Y
authors.initials: Y
authors.lastname: Yamasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Yamano
authors.forename: F
authors.initials: F
authors.lastname: Ohmori
authors.forename: K
authors.initials: K
authors.lastname: Ohkuma
authors.forename: Y
authors.initials: Y
authors.lastname: Ohnishi
authors.forename: M
authors.initials: M
authors.lastname: Yamamura
authors.forename: Y
authors.initials: Y
authors.lastname: Asano
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Ikeda
authors.forename: E
authors.initials: E
authors.lastname: Oda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000150:complications*; D008223:Lymphoma / Q000150:complications*; D008297:Male; D009101:Multiple Myeloma / Q000150:complications; D009181:Mycoses / Q000188:drug therapy*
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole